Compare CBU & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CBU | ADPT |
|---|---|---|
| Founded | 1866 | 2009 |
| Country | United States | United States |
| Employees | N/A | 624 |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 2.7B |
| IPO Year | 1994 | 2019 |
| Metric | CBU | ADPT |
|---|---|---|
| Price | $61.91 | $17.53 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 9 |
| Target Price | ★ $66.67 | $17.78 |
| AVG Volume (30 Days) | 248.3K | ★ 3.0M |
| Earning Date | 04-29-2026 | 05-05-2026 |
| Dividend Yield | ★ 3.02% | N/A |
| EPS Growth | 15.41 | ★ 63.89 |
| EPS | ★ 1.08 | N/A |
| Revenue | ★ $818,007,000.00 | $276,976,000.00 |
| Revenue This Year | $13.46 | $3.98 |
| Revenue Next Year | $7.75 | $22.72 |
| P/E Ratio | $57.35 | ★ N/A |
| Revenue Growth | 9.61 | ★ 54.77 |
| 52 Week Low | $51.12 | $9.96 |
| 52 Week High | $67.50 | $20.76 |
| Indicator | CBU | ADPT |
|---|---|---|
| Relative Strength Index (RSI) | 43.74 | 58.90 |
| Support Level | $60.93 | $14.87 |
| Resistance Level | $64.83 | $17.72 |
| Average True Range (ATR) | 1.61 | 1.36 |
| MACD | -0.29 | 0.01 |
| Stochastic Oscillator | 18.92 | 56.11 |
Community Financial System Inc is a diversified financial services company providing a broad array of banking and other financial services to retail, commercial, institutional, and governmental customers. The Company also offers comprehensive financial planning, trust administration, and wealth management services through its Community Bank Wealth Management operating unit. It has four reportable operating business segments: Banking and Corporate, Employee Benefit Services, Insurance Services, and Wealth Management Services. The group generates the majority of its revenue from the Banking and Corporate segment.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.